Opsoclonus myoclonus ataxia syndrome (OMAS) is an autoimmune disorder characterized by rapid, random, conjugate eye movements (opsoclonus), myoclonus, and ataxia. Given these symptoms, autoantibodies targeting the cerebellum or brainstem could mediate the disease or be markers of autoimmunity. In a subset of patients with OMAS, we identified such autoantibodies, which bind to non-synaptic puncta on the surface of live cultured cerebellar and brainstem neuronal dendrites. These findings implicate autoimmunity to a neuronal surface antigen in the pathophysiology of OMAS. Identification of the targeted antigen(s) could elucidate the mechanisms underlying OMAS and provide a biomarker for diagnosis and response to therapy.
Introduction
Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare but devastating disorder involving the acute onset of opsoclonus (rapid, random, multidirectional saccadic eye movements without intersaccadic intervals), myoclonus, and ataxia, as well as disordered mood or behavior. OMAS occurs as either a paraneoplastic or post-infectious autoimmune disorder (Digre, 1986; Wong, 2007) . In children 50% of cases are paraneoplastic and are associated with neuroblastoma; the remaining pediatric cases are believed to be post-infectious or to result from neuroblastoma that has regressed prior to onset of symptoms (Panzer and Dalmau, 2011) . OMAS also occurs in adults, where the associated tumors include breast, ovarian, and small cell lung cancers (Luque et al., 1991) . Patients with OMAS, regardless of tumor status, are treated with immunosuppressive therapies with variable responses, often with residual long-term neurocognitive deficits (Catsman-Berrevoets et al., 2009; De Grandis et al., 2009) .
Despite the initial description of OMAS more than 50 years ago (Kinsbourne, 1962) , little is understood about its underlying pathophysiology. For patients with paraneoplastic disease, expression of neuronal antigens within the tumor might trigger an autoimmune response that spreads to the brain. For patients with idiopathic OMAS, exposure to a virus may trigger a similar event. The symptoms of OMAS may point to the autoimmune target(s) in the cerebellum or pons. Ataxia results from dysfunction of the cerebellum, or cerebellar inflow/outflow tracts within the pons, midbrain, and thalamus. Opsoclonus is thought to originate from either the cerebellum (Wong et al., 2001) or dysfunction of omnipause neurons in the pons (Kim et al., 2007; Ramat et al., 2008) . As there is a minimal brain inflammation in OMAS (Kilgo and Schwartze, 1984) , autoantibodies in OMAS may directly bind to their target antigen, disrupting its function without causing significant inflammatory tissue destruction, analogous to what is seen in encephalitides associated with known neuronal surface antigens (Bien et al., 2012; Dalmau et al., 2007) . Various studies have reported autoantibodies in OMAS, including antibodies, now believed to be non-specific, directed against neurofilament proteins (Braxton et al., 1989; Noetzel et al., 1987) as well as recent reports describing antibodies to neurotransmitter receptors in a few patients with symptoms of OMAS as part of broader neuroimmune disorder (Höftberger et al., 2013; Petit-Pedrol et al., 2014; Smith et al., 2011) . In several larger series, although broad anti-neuronal reactivity is seen, no single autoantibody specific for OMAS has been identified (Antunes et al., 2000; Bataller et al., 2003) . Studies using flow cytometry have found serum antibodies recognizing neuroblastoma cells and cerebellar granule cells, but Journal of Neuroimmunology 286 (2015) 86-92 
